Unknown

Dataset Information

0

The Kinetics of Circulating Monocyte Subsets and Monocyte-Platelet Aggregates in the Acute Phase of ST-Elevation Myocardial Infarction: Associations with 2-Year Cardiovascular Events.


ABSTRACT: In experimental myocardial infarction (MI), a rise in cell counts of circulating monocyte subsets contributes to impaired myocardial healing and to atherosclerotic plaque destabilization. In humans, the prognostic role of monocyte subsets in patients suffering ST-elevation MI (STEMI) is still unclear. In the present study, we aimed to determine the kinetics of the 3 monocyte subsets (classical CD14++CD16-, intermediate CD14++CD16+, and nonclassical CD14+CD16++ monocytes), as well as the subset-specific monocyte-platelet aggregates (MPA), in acute STEMI followed by primary percutaneous coronary intervention (PCI), and their relationships with cardiovascular outcomes during a 2-year follow-up.Monocyte subsets and MPA were measured in 100 STEMI patients receiving primary PCI on days 1, 2, 3, 5, and 7 of symptom onset, which were compared with 60 stable coronary heart disease patients and 35 healthy volunteers. From day 1 to day 7, significant increases in the counts of CD14++CD16+ monocytes and CD14++CD16+ MPA were observed, with peak levels on day 2. During a median follow-up of 2.0 years, 28 first cardiovascular events (defined as cardiovascular death, nonfatal ischemic stroke, recurrent MI, need for emergency or repeat revascularization, and rehospitalization for heart failure) were recorded. After adjustment for confounders, CD14++CD16+ monocytosis (day 1 [HR: 3.428; 95% CI: 1.597-7.358; P?=?0.002], day 2 [HR: 4.835; 95% CI: 1.106-21.13; P?=?0.04], day 3 [HR: 2.734; 95% CI: 1.138-6.564; P?=?0.02], and day 7 [HR: 2.647; 95% CI: 1.196-5.861; P?=?0.02]), as well as increased levels of CD14++CD16+ MPA measured on all time points (days 1, 2, 3, 5, and 7), had predictive values for adverse cardiovascular events.In conclusion, our data show the expansion of the CD14++CD16+ monocyte subset during acute phase of STEMI has predictive values for 2-year adverse cardiovascular outcomes in patients treated with primary PCI. Future studies will be warranted to elucidate whether CD14++CD16+ monocytes may become a target cell population for new therapeutic strategies after STEMI.

SUBMITTER: Zhou X 

PROVIDER: S-EPMC4863763 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Kinetics of Circulating Monocyte Subsets and Monocyte-Platelet Aggregates in the Acute Phase of ST-Elevation Myocardial Infarction: Associations with 2-Year Cardiovascular Events.

Zhou Xin X   Liu Xin-Lin XL   Ji Wen-Jie WJ   Liu Jun-Xiang JX   Guo Zhao-Zeng ZZ   Ren Dong D   Ma Yong-Qiang YQ   Zeng Shan S   Xu Zhong-Wei ZW   Li Hong-Xia HX   Wang Peizhong Peter PP   Zhang Zhuoli Z   Li Yu-Ming YM   Benefield Brandon C BC   Zawada Adam M AM   Thorp Edward B EB   Lee Daniel C DC   Heine Gunnar H GH  

Medicine 20160501 18


In experimental myocardial infarction (MI), a rise in cell counts of circulating monocyte subsets contributes to impaired myocardial healing and to atherosclerotic plaque destabilization. In humans, the prognostic role of monocyte subsets in patients suffering ST-elevation MI (STEMI) is still unclear. In the present study, we aimed to determine the kinetics of the 3 monocyte subsets (classical CD14++CD16-, intermediate CD14++CD16+, and nonclassical CD14+CD16++ monocytes), as well as the subset-s  ...[more]

Similar Datasets

| S-EPMC8821091 | biostudies-literature
| S-EPMC5898983 | biostudies-literature
| S-EPMC5922709 | biostudies-other
| S-EPMC10858964 | biostudies-literature
| S-EPMC5501718 | biostudies-other
| S-EPMC7823877 | biostudies-literature
| S-EPMC6134176 | biostudies-other
| S-EPMC10432699 | biostudies-literature
| S-EPMC5883284 | biostudies-literature
| S-EPMC9964977 | biostudies-literature